NCI SBIR guests: biotech founders should start fundraising early, show clear data milestones and manage runway

Billy Baza, program director at the National Cancer Institute’s Small Business Innovation Research (SBIR) Development Center, hosted a podcast conversation with ImmunoPhotonics CEO Lou Alaruzzo and CSO David Anderson about fundraising strategies for biotech startups.

Alaruzzo and Anderson said founders should match investor type to the company’s stage: angels and incubators for very early work, venture funds and institutional investors for established proof of concept, and ultra‑high‑net‑worth individuals or institutions for clinical‑stage needs. "Every single stage has a different investor network," Anderson said, adding that founders should "focus your network building on the next stage that's coming ahead." The guests emphasized that investors often “bet on the jockey as much as they're betting on the science,” making leadership credibility and clear milestones vital.

Both guests urged founders to begin outreach early. "It always takes longer than you expect to raise funds," Alaruzzo said, recommending that teams use current progress to open conversations and negotiate follow‑on data milestones. The panel repeatedly noted that investors will ask for "more data," and recommended preparing concise progress updates and a clear development plan that outlines the studies and costs required to reach the next inflection point.

For chance interactions with high‑net‑worth individuals, Alaruzzo advised a tight, 30‑second pitch: "You better have your 30 second pitch down perfectly," he said, because many initial interactions are brief. He cautioned that those investors may expect deeper involvement after investing.

The guests also discussed when to seek dilutive capital after receiving NIH grants. Both recommended starting investor conversations while grant funds are being used, and using peer review feedback to improve resubmissions and to inform investor pitches. "Resubmit," the host said; data show better outcomes on resubmitted SBIR applications.

On equity and inventor arrangements, the panel offered forward‑looking guidance: equity should reflect future contributions and, where appropriate, be tied to milestones so inventors are rewarded as value is created.

The episode highlighted SBIR funding as a practical way to extend runway and validate programs. "Cash is king," the speakers said, noting that SBIR awards can both fund experiments and signal external validation to potential investors.

The conversation closed with practical networking advice — leverage incubators, LinkedIn, and industry conferences — and a reminder to prepare a commercialization plan and regulatory pathway that investors can evaluate when considering funding.

The podcast is part of NCI SBIR’s Innovation Lab series; listeners are directed to sbir.cancer.gov for resources and guidance.